Blueprint Medicines Corp 4
4 · Blueprint Medicines Corp · Filed Mar 20, 2017
Insider Transaction Report
Form 4
LEVIN MARK J
10% Owner
Transactions
- Sale
Common Stock
2017-03-16$40.74/sh−24,800$1,010,352→ 116,444 total - Sale
Common Stock
2017-03-16$41.55/sh−5,200$216,060→ 111,244 total
Holdings
- 3,453,753(indirect: See footnote)
Common Stock
Footnotes (3)
- [F1]This price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.33 to $41.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.
- [F2]This price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.34 to $41.84, inclusive.
- [F3]These shares are directly held by Third Rock Ventures II, L.P. ("TRV II"). The general partner of TRV II is Third Rock Ventures GP II, L.P. ("TRV GP II"). The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.